HC Wainwright Reiterates Buy Rating for Y-mAbs Therapeutics (NASDAQ:YMAB)

Y-mAbs Therapeutics (NASDAQ:YMAB)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a research note issued to investors on Monday,Benzinga reports. They currently have a $22.00 target price on the stock. HC Wainwright’s target price points to a potential upside of 219.30% from the company’s current price.

Other analysts have also recently issued research reports about the company. Oppenheimer initiated coverage on Y-mAbs Therapeutics in a research report on Monday, November 18th. They set an “outperform” rating and a $23.00 price target for the company. Brookline Capital Management assumed coverage on Y-mAbs Therapeutics in a report on Thursday, December 5th. They issued a “buy” rating and a $17.00 price target for the company. Finally, Wedbush reiterated an “outperform” rating and set a $23.00 price objective on shares of Y-mAbs Therapeutics in a research note on Friday. One analyst has rated the stock with a sell rating, seven have given a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Y-mAbs Therapeutics currently has an average rating of “Buy” and a consensus target price of $20.89.

Y-mAbs Therapeutics Trading Down 6.8 %

Shares of NASDAQ:YMAB opened at $6.89 on Monday. Y-mAbs Therapeutics has a 12-month low of $6.84 and a 12-month high of $20.90. The business’s fifty day simple moving average is $10.32 and its 200-day simple moving average is $12.13. The company has a market capitalization of $308.60 million, a PE ratio of -12.76 and a beta of 0.69.

Y-mAbs Therapeutics (NASDAQ:YMAB) last announced its earnings results on Friday, November 8th. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.02). Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. The business had revenue of $18.46 million for the quarter, compared to analysts’ expectations of $23.38 million. During the same quarter last year, the firm earned ($0.18) earnings per share. Research analysts predict that Y-mAbs Therapeutics will post -0.66 EPS for the current year.

Institutional Investors Weigh In On Y-mAbs Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. State Street Corp raised its position in shares of Y-mAbs Therapeutics by 50.4% during the 3rd quarter. State Street Corp now owns 1,209,781 shares of the company’s stock worth $15,909,000 after purchasing an additional 405,169 shares during the last quarter. Caligan Partners LP grew its stake in shares of Y-mAbs Therapeutics by 105.3% during the 3rd quarter. Caligan Partners LP now owns 1,195,253 shares of the company’s stock valued at $15,718,000 after buying an additional 613,175 shares during the period. Geode Capital Management LLC grew its stake in shares of Y-mAbs Therapeutics by 6.2% during the 3rd quarter. Geode Capital Management LLC now owns 813,489 shares of the company’s stock valued at $10,699,000 after buying an additional 47,846 shares during the period. Dimensional Fund Advisors LP lifted its holdings in shares of Y-mAbs Therapeutics by 15.7% during the 2nd quarter. Dimensional Fund Advisors LP now owns 484,431 shares of the company’s stock valued at $5,853,000 after acquiring an additional 65,732 shares in the last quarter. Finally, Millennium Management LLC lifted its holdings in shares of Y-mAbs Therapeutics by 23.8% during the 2nd quarter. Millennium Management LLC now owns 349,784 shares of the company’s stock valued at $4,225,000 after acquiring an additional 67,233 shares in the last quarter. 70.85% of the stock is currently owned by institutional investors and hedge funds.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.